```markdown DISCLAIMER.md # **DISCLAIMER FOR CVE-2026-0628 RESEARCH AND PROOF-OF-CONCEPT** **Author:** Sastra Adi Wiguna **Organization:** Purple Elite Teaming **Date:** January 29, 2026 **CVE Identifier:** CVE-2026-0628 **Research Title:** Origin CyberAnatomy Spoofing via Malicious WebView: Dissecting CVE-2026-0628 Chromium Extension Privilege Escalation --- ## **1. PURPOSE AND SCOPE** This research analyzes **CVE-2026-0628**, a high-severity vulnerability in Chromium's WebView policy enforcement mechanism (CVSS v3.1: 8.8). The purpose of this document and accompanying materials is **exclusively for academic, defensive security research, and authorized penetration testing**. The technical analysis, exploit demonstrations, and proof-of-concept code are provided **solely for the following purposes**: - **Vulnerability understanding and analysis** for security researchers. - **Detection engineering** to develop signatures for malicious activity. - **Mitigation strategy development** for system administrators and browser vendors. - **Authorized penetration testing and red team assessments** under explicit legal authorization. - **Responsible disclosure documentation** to assist in patch deployment and security hardening. --- ## **2. RESPONSIBLE USE STATEMENT** ### **2.1 Authorized Use Cases** Readers and users of this research are **strictly directed** to apply this information **only for defensive purposes**, including but not limited to: - **Patch deployment verification** for Chrome ≥143.0.7499.192 and Edge ≥143.0.3650.139. - **Extension blacklisting** via Group Policy Object (GPO) or enterprise management tools. - **Behavioral detection signature development** (e.g., YARA, Sysmon, Sigma rules). - **Enterprise browser hardening** through configuration baselines and security policies. - **Legitimate vulnerability research** conducted in isolated, non-production environments. ### **2.2 Prohibited Use Cases** The following activities are **explicitly prohibited** and constitute **unauthorized and unethical use** of this research: - **Offensive use** against any system without explicit, written authorization from the system owner. - **Weaponization** or integration into exploit kits, malware, or attack frameworks. - **Distribution to malicious actors** or entities known to engage in cybercrime. - **Exploitation of production systems**, including but not limited to corporate networks, government systems, or personal devices. - **Violation of applicable laws**, including computer fraud and abuse statutes, data protection regulations, and intellectual property rights. --- ## **3. LEGAL AND ETHICAL COMPLIANCE** ### **3.1 Compliance with Laws and Regulations** Users of this research **must comply** with all applicable laws and regulations, including but not limited to: - **Computer Fraud and Abuse Act (CFAA)** in the United States. - **General Data Protection Regulation (GDPR)** in the European Union. - **Local cybersecurity and data protection laws** in the user's jurisdiction. - **Organizational security policies** governing vulnerability research and penetration testing. ### **3.2 Authorization Requirements** Any attempt to reproduce or test the vulnerability **must** be conducted under **explicit legal authorization**, including: - **Written permission** from the owner of the target system. - **Compliance with organizational policies** for security testing. - **Adherence to responsible disclosure practices**, including coordination with vendors and affected parties. Failure to obtain proper authorization **may result in legal consequences**, including civil and criminal liability. --- ## **4. ENVIRONMENTAL RESTRICTIONS** ### **4.1 Isolated Laboratory Requirements** All technical demonstrations, exploit testing, and vulnerability reproduction **must** be conducted in **isolated laboratory environments** with the following minimum requirements: - **Virtualized systems** with no network connectivity to production environments or the public internet. - **Snapshot and rollback capabilities** to ensure containment of any unintended effects. - **Logging and monitoring** to track all actions and detect anomalies. - **Restricted access** limited to authorized security personnel. ### **4.2 Prohibited Environments** Under no circumstances should this research be reproduced or tested in the following environments: - **Production systems** used for business operations, personal use, or critical infrastructure. - **Cloud environments** without explicit isolation and authorization. - **Systems containing sensitive or personal data**, including but not limited to PII, financial records, or intellectual property. - **Third-party networks or systems** without written consent from the owner. --- ## **5. TECHNICAL AND OPERATIONAL RISKS** ### **5.1 Potential Risks of Reproduction** Reproducing this vulnerability **carries inherent risks**, including but not limited to: - **System compromise** due to unintended exploitation or misconfiguration. - **Data leakage** if testing is conducted in non-isolated environments. - **Denial-of-service (DoS)** conditions affecting the stability of the test system. - **Unintended propagation** of malicious code or extensions. ### **5.2 Risk Mitigation Measures** To mitigate these risks, users **must** implement the following controls: - **Use non-persistent virtual machines** that can be reverted to a clean state. - **Disable network connectivity** during testing to prevent accidental exposure. - **Monitor system logs** for signs of unintended activity. - **Validate all inputs and outputs** to ensure no malicious payloads are executed outside the test environment. --- ## **6. CITATION AND ATTRIBUTION** ### **6.1 Citation Requirements** Any reproduction, distribution, or reference to this research **must** include the following: - **Full preservation of this disclaimer** in all derived works. - **Proper citation** of the original research, including the author, title, and publication date. - **Clear attribution** to the corresponding author for any inquiries or clarifications. ### **6.2 Example Citation Format** ``` Sastra Adi Wiguna. (January 2026). *Origin CyberAnatomy Spoofing via Malicious WebView: Dissecting CVE-2026-0628 Chromium Extension Privilege Escalation*. Purple Elite Teaming. ``` --- ## **7. PATCH AND MITIGATION RECOMMENDATIONS** ### **7.1 Immediate Actions** Organizations and individuals **must** take the following steps to mitigate exposure to CVE-2026-0628: - **Verify patch compliance** for Chrome ≥143.0.7499.192 and Edge ≥143.0.3650.139. - **Deploy Group Policy Objects (GPO)** to blacklist malicious extensions and restrict WebView usage. - **Implement behavioral detection rules** (e.g., YARA, Sysmon) to identify exploitation attempts. - **Conduct security awareness training** to educate users about the risks of installing untrusted extensions. ### **7.2 Long-Term Mitigation Strategies** - **Enterprise browser hardening** through configuration baselines and security policies. - **Regular vulnerability assessments** to identify and remediate similar vulnerabilities. - **Incident response planning** to address potential exploits and breaches. - **Collaboration with vendors** to report vulnerabilities and validate patches. --- ## **8. CONTACT AND SUPPORT** ### **8.1 Corresponding Author** For questions regarding defensive security measures, mitigation guidance, or responsible disclosure, contact: **Name:** Sastra Adi Wiguna **Organization:** Purple Elite Teaming **Email:** [REDACTED FOR PUBLIC REPOSITORY] **GitHub:** [REDACTED FOR PUBLIC REPOSITORY] ### **8.2 Reporting Vulnerabilities** If you discover additional vulnerabilities or variants of CVE-2026-0628, **please report them responsibly** to the corresponding vendor: - **Google Chrome Security Team:** [chrome-reports@google.com](mailto:chrome-reports@google.com) - **Microsoft Edge Security Team:** [secure@microsoft.com](mailto:secure@microsoft.com) --- ## **9. LIABILITY DISCLAIMER** ### **9.1 No Warranty** This research is provided **"as is"** without any warranties, express or implied, including but not limited to: - **Merchantability** or fitness for a particular purpose. - **Accuracy, completeness, or reliability** of the information. - **Freedom from errors, omissions, or inaccuracies**. ### **9.2 Limitation of Liability** The author, contributors, and affiliated organizations **shall not be liable** for any direct, indirect, incidental, special, or consequential damages arising from: - The use or inability to use this research. - Unauthorized or improper use of the provided materials. - Any errors, omissions, or inaccuracies in the documentation. - Any actions taken based on the information contained herein. Users assume **full responsibility** for their use of this research and agree to **indemnify and hold harmless** the author and contributors from any claims or liabilities. --- ## **10. FINAL NOTES** ### **10.1 Ethical Research Commitment** This research adheres to the principles of **responsible disclosure** and **ethical hacking**. The author is committed to **transparency, integrity, and collaboration** with the security community to improve cybersecurity defenses. ### **10.2 Acknowledgment of Risks** Users acknowledge that reproducing this vulnerability **involves significant risks** and agree to **assume all responsibility** for their actions. The author and contributors **do not endorse or condone** any unauthorized or malicious use of this research. ### **10.3 Encouragement for Responsible Disclosure** Readers are encouraged to **report vulnerabilities responsibly** and contribute to the **collective effort** of improving cybersecurity. Together, we can create a safer digital environment for all. --- **© 2026 Sastra Adi Wiguna. All rights reserved.** This disclaimer is **immutable** and **must** accompany all reproductions or distributions of this research. ```